A WEP Clinical White Paper
With Every Patient
Executive Summary
Cell and gene therapy (CGT) trials operate at the intersection of scientific precision and operational complexity. These programs require highly controlled environments to ensure product integrity, patient safety, and regulatory compliance – necessitating centralized execution for core activities, such as product administration, safety monitoring, and specialized assessments. However, reliance on fully site-centric models introduces structural inefficiencies that directly impact study performance. These include limited access to qualified treatment centers, significant patient and caregiver burden, and challenges in maintaining engagement over long-term follow-up periods.
Hybrid clinical trial models provide a pragmatic evolution of this framework. By selectively distributing appropriate trial activities, while maintaining centralization where required, Sponsors can reduce operational friction without compromising rigor. For clinical development and operations teams, hybrid execution is not a shift toward decentralization for its own sake, but a strategic mechanism to improve enrollment, retention, data completeness, and overall study resilience. When designed intentionally, hybrid models enable Sponsors to balance control with flexibility, aligning trial execution more closely with both protocol demands and patient realities.
Introduction
The clinical development landscape for CGT therapies has expanded rapidly, moving from early proof-of-concept studies into increasingly complex, global programs. This shift has introduced a level of operational demand that traditional clinical trial models were not designed to accommodate. Unlike conventional therapeutics, CGT trials often require tightly coordinated manufacturing and delivery processes, strict adherence to chain of identity and custody controls, and highly specialized clinical procedures. These factors inherently limit where and how trials can be conducted, reinforcing reliance on a small number of experienced sites.
At the same time, the populations targeted by these therapies, often patients with rare diseases, advanced cancers, or other serious conditions, are frequently dispersed geographically and require significant support to participate in clinical research. The burden placed on patients and caregivers is not incidental; it is a defining characteristic of CGT trials. Frequent travel, intensive visit schedules, and long-term follow-up requirements can create barriers to both enrollment and sustained participation.
This creates a fundamental challenge for Sponsors: maintaining the rigor required for advanced therapies while improving access, reducing burden, and ensuring long-term engagement. Hybrid models address this challenge by enabling a more flexible and patient-aligned approach to execution. Rather than replacing centralized trial infrastructure, hybrid approaches extend it, allowing Sponsors to preserve control over critical activities while optimizing how and where supporting activities are delivered.
Limitations of Traditional Site-Centric Models in CGT
Traditional site-centric models have served as the foundation of clinical trial execution, particularly in complex therapeutic areas. In CGT, however, these models reveal structural limitations that directly impact operational performance. One of the most significant constraints is the reliance on a limited number of centers of excellence. These sites possess the expertise and infrastructure required for advanced therapies, but their geographic concentration restricts patient access and creates bottlenecks in enrollment capacity.
Operational complexity further compounds these limitations. CGT trials often involve multi-step workflows that must be precisely coordinated across manufacturing, logistics, and clinical delivery. Any disruption in this chain can impact treatment timing, patient scheduling, or data collection. Sites must manage these dependencies while also handling intensive monitoring requirements and high-touch patient engagement, increasing the burden on already resource-constrained environments.
From the patient perspective, the demands of participation can be substantial. Travel to distant sites, extended visit durations, and the need for caregiver involvement create logistical and emotional strain. Over time, these factors contribute to attrition risk, particularly in studies requiring long-term follow-up. For Sponsors, this translates into measurable operational challenges, including slower enrollment, increased protocol deviations, incomplete datasets, and extended timelines.
These issues are not a reflection of poor execution but of structural misalignment between traditional models and the realities of CGT development. While centralized models remain essential, they must be complemented by approaches that reduce unnecessary burden and improve access without introducing additional risk.
Defining Hybrid Execution in CGT Trials
Hybrid clinical trial models are best understood not as a binary shift away from site-based execution, but as a continuum in which specific activities are distributed based on feasibility, risk, and value. In CGT trials, this distinction is particularly important because not all activities can be decentralized. Product administration, for example, often requires specialized facilities, trained personnel, and real-time safety oversight. Similarly, processes tied to chain of identity and custody demand tightly controlled environments to ensure product integrity.
At the same time, a significant portion of trial activities are not inherently dependent on the site. Follow-up visits, patient education, symptom monitoring, and certain sample collections can often be conducted outside traditional clinical settings without compromising quality. When appropriately designed, these distributed activities can reduce travel requirements, improve scheduling flexibility, and enhance patient engagement.
The value of hybrid execution lies in its ability to extend the functional reach of the site. Rather than shifting responsibility away from investigators, hybrid models allow sites to maintain oversight while leveraging additional capabilities to support patients more effectively. This approach preserves accountability and data integrity while enabling a more adaptable execution model.
For Sponsors, the key is not identifying what can be decentralized in isolation, but determining where distribution creates meaningful operational or patient benefit. This requires a disciplined, protocol-driven approach to hybridization-one that balances flexibility with control and avoids introducing fragmentation into already complex studies.
Hybrid Models as a Retention and Risk Mitigation Strategy
Retention is one of the most critical determinants of success in CGT trials. Given the small patient populations and long-term follow-up requirements typical of these studies, even modest levels of attrition can have a disproportionate impact on data completeness and study timelines. Missed visits, incomplete assessments, and early withdrawals all introduce variability that can affect both operational performance and regulatory outcomes.
The drivers of attrition in CGT trials are closely tied to patient burden. Frequent travel, complex visit schedules, and the cumulative demands of participation can erode engagement over time. For pediatric and rare disease populations, these challenges are often amplified by caregiver constraints, further increasing the risk of dropout.
Hybrid models address these challenges by reducing avoidable burden while maintaining the structure and oversight required for high-quality data collection. Remote follow-up visits, home-based support services, and digital engagement tools enable patients to remain connected to the study without the need for constant site interaction. This is particularly important in long-term follow-up phases, where maintaining engagement over multiple years can be difficult under traditional models.
From an operational perspective, hybrid execution serves as a proactive risk mitigation strategy. By improving adherence and reducing barriers to participation, Sponsors can enhance data completeness, stabilize timelines, and reduce the likelihood of protocol deviations. In this context, patient-centric design is not simply an ethical or experiential consideration, it is a core component of study performance and scientific validity.
Operational Design Considerations
The effectiveness of hybrid models is determined by the quality of their operational design. Introducing distributed elements into a trial without appropriate integration can increase complexity rather than reduce it. As such, hybrid execution must be approached as a deliberate operating model, not a collection of decentralized tools.
A critical starting point is the preservation of investigator oversight. In CGT trials, the site is the central hub for clinical decision-making, safety management, and protocol execution. Any distributed activity must be clearly linked back to the site, with defined responsibilities, communication pathways, and escalation procedures. Without this structure, there is a risk of fragmentation that can compromise both oversight and data integrity.
Equally important is the coordination of vendors and support services. Hybrid models often involve multiple external partners, including mobile healthcare providers, laboratories, logistics teams, and digital platform vendors. These components must operate within a unified framework that aligns with site workflows and protocol requirements. Poor integration can lead to inefficiencies, delays, and inconsistencies in data collection.
Risk-based oversight is another essential component. Distributed activities must meet the same standards for quality, training, and documentation as site-based activities. This often requires more structured monitoring and governance, not less. Data flow must also be carefully managed to ensure that information generated outside the site is captured, integrated, and made visible in real time to both investigators and Sponsors.
Ultimately, the goal of operational design is to ensure that hybrid execution simplifies, rather than complicates, trial delivery. This requires disciplined decision-making and a clear focus on where hybrid elements add value.
A Fit-for-Purpose Framework for Hybridization
Given the variability across CGT programs, there is no universal hybrid model that can be applied to all studies. Instead, Sponsors must adopt a fit-for-purpose framework that evaluates hybrid opportunities at the level of individual activities.
This framework begins with three fundamental questions: Does the activity require specialized site infrastructure? Can it be performed outside the site without increasing risk? And, will distributing the activity meaningfully reduce burden or improve compliance? These questions shift the focus from what is technically possible to what is operationally and scientifically appropriate.
Importantly, this evaluation should consider the specific characteristics of the patient population. Studies involving highly fragile patients, complex treatment regimens, or significant caregiver involvement may require different levels of hybridization than those with more stable populations. Geographic factors, disease progression, and long-term follow-up requirements all influence where distributed support can create value.
Hybridization should also be viewed as dynamic rather than static. As programs progress through development phases, the balance between centralized and distributed activities may evolve. Early-phase studies may require tighter control, while later-phase or post-approval studies may allow for greater flexibility. Sponsors that approach hybridization as an adaptive capability, rather than a fixed design choice, will be better positioned to optimize execution over time.
The Future: Intelligently Distributed Trial Models
The future of CGT trial execution will not be defined by a shift toward fully decentralized models. Instead, it will be shaped by the development of intelligently distributed operating models that combine centralized control with selective flexibility. These models recognize that precision and adaptability are not competing priorities, but complementary requirements.
In this framework, critical activities remain anchored at specialized sites, while supporting activities are extended beyond the site where doing so improves access, reduces burden, or enhances continuity of care. The result is a more adaptive execution model that aligns with both the scientific demands of advanced therapies and the practical realities of patient participation.
For Sponsors, this represents a shift in mindset. Hybrid execution is not about adopting new tools, but about redesigning operating models to better support complex programs. As CGT pipelines expand and commercialization considerations become increasingly relevant, the ability to scale execution without sacrificing quality will become a key differentiator.
Conclusion
Cell and gene therapy trials require a balance between control and flexibility that traditional models alone cannot fully provide. Hybrid approaches offer a path forward by enabling Sponsors to extend trial execution beyond the site in a way that reduces burden, improves retention, and strengthens overall study performance.
The objective is not to decentralize indiscriminately, but to design execution models that are aligned with the unique demands of each program. When implemented thoughtfully, hybrid models enhance, not replace, the rigor of traditional approaches.
As CGT development continues to evolve, Sponsors that embrace intelligently distributed execution will be better positioned to deliver efficient, scalable, and patient-centered trials. In this environment, operational innovation is not optional, it is essential to realizing the full potential of advanced therapies.
